You are here: Industry Insights > gilead

News List

Gilead Commits $100M to Tackle the HIV/AIDS Epidemic in the Southern U.S. biospace
December 05, 2017
Gilead Announces 10-Year, $100 Million Commitment to Address the HIV/AIDS Epidemic in the Southern United States
Gilead lowers the price to launche hep C drug Sovaldi in China pharmafile
November 30, 2017
Gilead has officially launched its hepatitis C drug Sovaldi (sofosbuvir) in the Chinese market, but with one major caveat: it will cost 58,980 yuan in the region, just one-fifth of its price tag in the US – a price which has fallen rapidly from the $84,0
With Kite in the bag, Gilead boosts oncology chief Riva to the head table fiercepharma
October 18, 2017
Riva’s new job comes with a seat on Gilead’s top leadership team, and it puts him in charge of all of Gilead’s oncology programs, including cell therapy R&D.
Gilead Sciences to acquire Kite Pharma for $11.9 Billion biospectrumasia
August 30, 2017
Kite's most advanced therapy candidate, axicabtagene ciloleucel (axi-cel), is a CAR T therapy currently under priority review by the U.S. Food and Drug Administration (FDA)
Gilead set to open California production campus for up to 500 workers fiercepharma
August 16, 2017
Gilead is set to open a new manufacturing campus in California where it will make AmBisome and package a variety of its drugs.
Gilead set to open $250m, 23-acre campus pharmafile
August 16, 2017
Gilead is set for the grand unveiling of its new facility in La Verne, Southern California, after several years of work. The facility, once it is running at full capacity, is it to create jobs for 500 workers.
Gilead's Q2 results outpace analyst expectations firstwordpharma
July 27, 2017
Gilead Sciences announced second-quarter results Wednesday showing that the company's net income was $3.1 billion, compared to $3.5 billion for the corresponding 2016 period.
Gilead’s fixed-dose (BIC/FTC/TAF) combination for HIV show high tolerability europeanpharmaceuticalreview
July 25, 2017
Phase 3 trials of Gilead’s fixed-dose (BIC/FTC/TAF) combination for HIV show high tolerability and low resistance
Gilead’s new HIV therapy under EU review pharmatimes
July 17, 2017
European regulators are now reviewing Gilead’s fixed-dose combination of bictegravir (BIC), emtricitabine and tenofovir alafenamide as a treatment for HIV-1 infection.
EMA validates Gilead Sciences’ marketing application for BIC/FTC/TAF combination pharmaceutical-technology
July 17, 2017
US biopharmaceutical company Gilead Sciences’ marketing authorisation application (MAA) for a fixed-dose drug combination to treat HIV-1 infection in adults has been fully validated and is currently under evaluation by the European Medicines Agency (EMA).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page